Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272

1.

Light-Controlled Mammalian Cells and Their Therapeutic Applications in Synthetic Biology.

Mansouri M, Strittmatter T, Fussenegger M.

Adv Sci (Weinh). 2018 Sep 30;6(1):1800952. doi: 10.1002/advs.201800952. eCollection 2019 Jan 9. Review.

2.

Synthetic Biology: Engineering Mammalian Cells to Control Cell-to-Cell Communication at Will.

Kojima R, Fussenegger M.

Chembiochem. 2018 Dec 27. doi: 10.1002/cbic.201800682. [Epub ahead of print]

PMID:
30589185
3.

Purity by design: Reducing impurities in bioproduction by stimulus-controlled global translational downregulation of non-product proteins.

Bojar D, Fuhrer T, Fussenegger M.

Metab Eng. 2019 Mar;52:110-123. doi: 10.1016/j.ymben.2018.11.007. Epub 2018 Nov 20.

PMID:
30468874
4.

Optogenetic Medicine: Synthetic Therapeutic Solutions Precision-Guided by Light.

Ye H, Fussenegger M.

Cold Spring Harb Perspect Med. 2018 Oct 5. pii: a034371. doi: 10.1101/cshperspect.a034371. [Epub ahead of print]

PMID:
30291146
5.

A synthetic free fatty acid-regulated transgene switch in mammalian cells and mice.

Liu Y, Charpin-El Hamri G, Ye H, Fussenegger M.

Nucleic Acids Res. 2018 Oct 12;46(18):9864-9874. doi: 10.1093/nar/gky805.

6.

Engineering mammalian cells for disease diagnosis and treatment.

P Teixeira A, Fussenegger M.

Curr Opin Biotechnol. 2019 Feb;55:87-94. doi: 10.1016/j.copbio.2018.08.008. Epub 2018 Sep 6. Review.

PMID:
30195188
7.

Engineering Whole Mammalian Cells for Target-Cell-Specific Invasion/Fusion.

Kojima R, Fussenegger M.

Adv Sci (Weinh). 2018 May 8;5(7):1700971. doi: 10.1002/advs.201700971. eCollection 2018 Jul.

8.

Immunomimetic Designer Cells Protect Mice from MRSA Infection.

Liu Y, Bai P, Woischnig AK, Charpin-El Hamri G, Ye H, Folcher M, Xie M, Khanna N, Fussenegger M.

Cell. 2018 Jul 12;174(2):259-270.e11. doi: 10.1016/j.cell.2018.05.039. Epub 2018 Jun 21.

9.

Caffeine-inducible gene switches controlling experimental diabetes.

Bojar D, Scheller L, Hamri GC, Xie M, Fussenegger M.

Nat Commun. 2018 Jun 19;9(1):2318. doi: 10.1038/s41467-018-04744-1.

10.

Designing cell function: assembly of synthetic gene circuits for cell biology applications.

Xie M, Fussenegger M.

Nat Rev Mol Cell Biol. 2018 Aug;19(8):507-525. doi: 10.1038/s41580-018-0024-z. Review.

PMID:
29858606
11.

A cell-penetrating artificial metalloenzyme regulates a gene switch in a designer mammalian cell.

Okamoto Y, Kojima R, Schwizer F, Bartolami E, Heinisch T, Matile S, Fussenegger M, Ward TR.

Nat Commun. 2018 May 16;9(1):1943. doi: 10.1038/s41467-018-04440-0.

12.

Designer cells programming quorum-sensing interference with microbes.

Sedlmayer F, Hell D, Müller M, Ausländer D, Fussenegger M.

Nat Commun. 2018 May 8;9(1):1822. doi: 10.1038/s41467-018-04223-7.

13.

Generalized extracellular molecule sensor platform for programming cellular behavior.

Scheller L, Strittmatter T, Fuchs D, Bojar D, Fussenegger M.

Nat Chem Biol. 2018 Jul;14(7):723-729. doi: 10.1038/s41589-018-0046-z. Epub 2018 Apr 23.

PMID:
29686358
14.

Synthetic biology-based cellular biomedical tattoo for detection of hypercalcemia associated with cancer.

Tastanova A, Folcher M, Müller M, Camenisch G, Ponti A, Horn T, Tikhomirova MS, Fussenegger M.

Sci Transl Med. 2018 Apr 18;10(437). pii: eaap8562. doi: 10.1126/scitranslmed.aap8562.

PMID:
29669854
15.

Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson's disease treatment.

Kojima R, Bojar D, Rizzi G, Hamri GC, El-Baba MD, Saxena P, Ausländer S, Tan KR, Fussenegger M.

Nat Commun. 2018 Apr 3;9(1):1305. doi: 10.1038/s41467-018-03733-8.

16.

Programmable full-adder computations in communicating three-dimensional cell cultures.

Ausländer D, Ausländer S, Pierrat X, Hellmann L, Rachid L, Fussenegger M.

Nat Methods. 2018 Jan;15(1):57-60. doi: 10.1038/nmeth.4505. Epub 2017 Dec 4.

PMID:
29200199
17.

Nonimmune cells equipped with T-cell-receptor-like signaling for cancer cell ablation.

Kojima R, Scheller L, Fussenegger M.

Nat Chem Biol. 2018 Jan;14(1):42-49. doi: 10.1038/nchembio.2498. Epub 2017 Nov 13.

18.

Sensing and responding to allergic response cytokines through a genetically encoded circuit.

Chassin H, Geering B, Schukur L, Ausländer D, Lang B, Fussenegger M.

Nat Commun. 2017 Oct 24;8(1):1101. doi: 10.1038/s41467-017-01211-1.

19.

Editorial Special Issue on the Occasion of Prof. Dr. Alf Pühler's 75th birthday.

Alves PM, Becker A, Blöcker H, Chan RL, Chen GG, Fussenegger M, Kondo A, Kourist R, Schwab H, Seo JH, Sensen CW, Sensen M, Scrienc F.

J Biotechnol. 2017 Sep 10;257:1. doi: 10.1016/j.jbiotec.2017.07.013. No abstract available.

PMID:
28818445
20.

Design of Synthetic Promoters for Gene Circuits in Mammalian Cells.

Saxena P, Bojar D, Fussenegger M.

Methods Mol Biol. 2017;1651:263-273. doi: 10.1007/978-1-4939-7223-4_19.

PMID:
28801913
21.

Generation of glucose-sensitive insulin-secreting beta-like cells from human embryonic stem cells by incorporating a synthetic lineage-control network.

Saxena P, Bojar D, Zulewski H, Fussenegger M.

J Biotechnol. 2017 Oct 10;259:39-45. doi: 10.1016/j.jbiotec.2017.07.018. Epub 2017 Jul 22.

PMID:
28739109
22.

Quorum-Quenching Human Designer Cells for Closed-Loop Control of Pseudomonas aeruginosa Biofilms.

Sedlmayer F, Jaeger T, Jenal U, Fussenegger M.

Nano Lett. 2017 Aug 9;17(8):5043-5050. doi: 10.1021/acs.nanolett.7b02270. Epub 2017 Jul 13.

PMID:
28703595
23.

Synthetic biology-inspired therapies for metabolic diseases.

Teixeira AP, Fussenegger M.

Curr Opin Biotechnol. 2017 Oct;47:59-66. doi: 10.1016/j.copbio.2017.06.004. Epub 2017 Jun 26. Review.

PMID:
28662442
24.

Self-adjusting synthetic gene circuit for correcting insulin resistance.

Ye H, Xie M, Xue S, Charpin-El Hamri G, Yin J, Zulewski H, Fussenegger M.

Nat Biomed Eng. 2017 Jan;1(1):0005. doi: 10.1038/s41551-016-0005. Epub 2016 Dec 19.

25.

Smartphone-controlled optogenetically engineered cells enable semiautomatic glucose homeostasis in diabetic mice.

Shao J, Xue S, Yu G, Yu Y, Yang X, Bai Y, Zhu S, Yang L, Yin J, Wang Y, Liao S, Guo S, Xie M, Fussenegger M, Ye H.

Sci Transl Med. 2017 Apr 26;9(387). pii: eaal2298. doi: 10.1126/scitranslmed.aal2298.

PMID:
28446682
26.

Synthetic RNA-based switches for mammalian gene expression control.

Ausländer S, Fussenegger M.

Curr Opin Biotechnol. 2017 Dec;48:54-60. doi: 10.1016/j.copbio.2017.03.011. Epub 2017 Apr 4. Review.

PMID:
28388465
27.

A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes.

Xue S, Yin J, Shao J, Yu Y, Yang L, Wang Y, Xie M, Fussenegger M, Ye H.

Mol Ther. 2017 Feb 1;25(2):443-455. doi: 10.1016/j.ymthe.2016.11.008.

28.

Designed cell consortia as fragrance-programmable analog-to-digital converters.

Müller M, Ausländer S, Spinnler A, Ausländer D, Sikorski J, Folcher M, Fussenegger M.

Nat Chem Biol. 2017 Mar;13(3):309-316. doi: 10.1038/nchembio.2281. Epub 2017 Jan 16.

PMID:
28092361
29.

Synthetic Biology-The Synthesis of Biology.

Ausländer S, Ausländer D, Fussenegger M.

Angew Chem Int Ed Engl. 2017 Jun 1;56(23):6396-6419. doi: 10.1002/anie.201609229. Epub 2017 Apr 25. Review.

PMID:
27943572
30.

β-cell-mimetic designer cells provide closed-loop glycemic control.

Xie M, Ye H, Wang H, Charpin-El Hamri G, Lormeau C, Saxena P, Stelling J, Fussenegger M.

Science. 2016 Dec 9;354(6317):1296-1301.

PMID:
27940875
31.

Synthetic Biology: Innovative approaches for pharmaceutics and drug delivery.

Deans TL, Grainger DW, Fussenegger M.

Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):1-2. doi: 10.1016/j.addr.2016.08.013. Epub 2016 Sep 18. No abstract available.

PMID:
27653994
32.

Engineering of synthetic gene circuits for (re-)balancing physiological processes in chronic diseases.

Schukur L, Fussenegger M.

Wiley Interdiscip Rev Syst Biol Med. 2016 Sep;8(5):402-22. doi: 10.1002/wsbm.1345. Epub 2016 Jun 24. Review.

PMID:
27341681
33.

The best of both worlds: reaping the benefits from mammalian and bacterial therapeutic circuits.

Bojar D, Fussenegger M.

Curr Opin Chem Biol. 2016 Oct;34:11-19. doi: 10.1016/j.cbpa.2016.05.012. Epub 2016 May 26. Review.

PMID:
27236825
34.

Engineering Gene Circuits for Mammalian Cell-Based Applications.

Ausländer S, Fussenegger M.

Cold Spring Harb Perspect Biol. 2016 Jul 1;8(7). pii: a023895. doi: 10.1101/cshperspect.a023895. Review.

35.

Toward a world of theranostic medication: Programming biological sentinel systems for therapeutic intervention.

Kojima R, Aubel D, Fussenegger M.

Adv Drug Deliv Rev. 2016 Oct 1;105(Pt A):66-76. doi: 10.1016/j.addr.2016.05.006. Epub 2016 May 14. Review.

PMID:
27189230
36.

Synthetic biology-application-oriented cell engineering.

Xie M, Haellman V, Fussenegger M.

Curr Opin Biotechnol. 2016 Aug;40:139-148. doi: 10.1016/j.copbio.2016.04.005. Epub 2016 Apr 29. Review.

PMID:
27135809
37.

A synthetic biology-based device prevents liver injury in mice.

Bai P, Ye H, Xie M, Saxena P, Zulewski H, Charpin-El Hamri G, Djonov V, Fussenegger M.

J Hepatol. 2016 Jul;65(1):84-94. doi: 10.1016/j.jhep.2016.03.020. Epub 2016 Apr 9.

38.

A programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cells.

Saxena P, Heng BC, Bai P, Folcher M, Zulewski H, Fussenegger M.

Nat Commun. 2016 Apr 11;7:11247. doi: 10.1038/ncomms11247.

39.

Engineering a ribozyme cleavage-induced split fluorescent aptamer complementation assay.

Ausländer S, Fuchs D, Hürlemann S, Ausländer D, Fussenegger M.

Nucleic Acids Res. 2016 Jun 2;44(10):e94. doi: 10.1093/nar/gkw117. Epub 2016 Mar 2.

40.

Synthetic gene network restoring endogenous pituitary-thyroid feedback control in experimental Graves' disease.

Saxena P, Charpin-El Hamri G, Folcher M, Zulewski H, Fussenegger M.

Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1244-9. doi: 10.1073/pnas.1514383113. Epub 2016 Jan 19.

41.

Synthetic biology: applying biological circuits beyond novel therapies.

Dobrin A, Saxena P, Fussenegger M.

Integr Biol (Camb). 2016 Apr 18;8(4):409-30. doi: 10.1039/c5ib00263j. Epub 2015 Dec 24. Review.

PMID:
26705548
42.

Overexpression of YY1 increases the protein production in mammalian cells.

Tastanova A, Schulz A, Folcher M, Tolstrup A, Puklowski A, Kaufmann H, Fussenegger M.

J Biotechnol. 2016 Feb 10;219:72-85. doi: 10.1016/j.jbiotec.2015.12.005. Epub 2015 Dec 10.

PMID:
26686315
43.

Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis.

Schukur L, Geering B, Charpin-El Hamri G, Fussenegger M.

Sci Transl Med. 2015 Dec 16;7(318):318ra201. doi: 10.1126/scitranslmed.aac4964.

PMID:
26676608
44.

Identification of Novel Death-Associated Protein Kinase 2 Interaction Partners by Proteomic Screening Coupled with Bimolecular Fluorescence Complementation.

Geering B, Zokouri Z, Hürlemann S, Gerrits B, Ausländer D, Britschgi A, Tschan MP, Simon HU, Fussenegger M.

Mol Cell Biol. 2015 Oct 19;36(1):132-43. doi: 10.1128/MCB.00515-15. Print 2016 Jan 1.

45.

Human whole-blood culture system for ex vivo characterization of designer-cell function.

Schukur L, Geering B, Fussenegger M.

Biotechnol Bioeng. 2016 Mar;113(3):588-97. doi: 10.1002/bit.25828. Epub 2015 Sep 30.

PMID:
26348251
46.

Synthetic Biology--Toward Therapeutic Solutions.

Haellman V, Fussenegger M.

J Mol Biol. 2016 Feb 27;428(5 Pt B):945-62. doi: 10.1016/j.jmb.2015.08.020. Epub 2015 Sep 1. Review.

PMID:
26334368
47.

Novel theranostic agents for next-generation personalized medicine: small molecules, nanoparticles, and engineered mammalian cells.

Kojima R, Aubel D, Fussenegger M.

Curr Opin Chem Biol. 2015 Oct;28:29-38. doi: 10.1016/j.cbpa.2015.05.021. Epub 2015 Jun 5. Review.

PMID:
26056952
48.

Mammalian designer cells: Engineering principles and biomedical applications.

Xie M, Fussenegger M.

Biotechnol J. 2015 Jul;10(7):1005-18. doi: 10.1002/biot.201400642. Epub 2015 May 26. Review.

PMID:
26010998
49.

Cosmetics-triggered percutaneous remote control of transgene expression in mice.

Wang H, Ye H, Xie M, Daoud El-Baba M, Fussenegger M.

Nucleic Acids Res. 2015 Aug 18;43(14):e91. doi: 10.1093/nar/gkv326. Epub 2015 May 5.

50.

A synthetic cGMP-sensitive gene switch providing Viagra(®)-controlled gene expression in mammalian cells and mice.

Kim T, Folcher M, Charpin-El Hamri G, Fussenegger M.

Metab Eng. 2015 May;29:169-179. doi: 10.1016/j.ymben.2015.03.016. Epub 2015 Apr 2.

PMID:
25843350

Supplemental Content

Loading ...
Support Center